What is the current stock price of Curative Biotechnology, Inc. (CUBT)?

As of the latest market data, Curative Biotechnology, Inc. (CUBT) is trading at $1.00. The stock has seen a loss of -16.67% today.

Does Curative Biotechnology, Inc. (CUBT) pay a dividend?

Based on current data, Curative Biotechnology, Inc. does not have a confirmed active dividend policy.

What is the market cap of Curative Biotechnology, Inc.?

The current market capitalization of Curative Biotechnology, Inc. (CUBT) is approximately unavailable.

CUBT

Curative Biotechnology, Inc.·Healthcare

1.00

16.667%(−0.20)

Market Closed

1.79

79.000%(+0.79)

After Hours

Last Updated: — ET

52W L: $0.0052W H: $1.79

CUBT NEWS

globenewswire.com

Mar 23

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m.

globenewswire.com

Mar 23

Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split ("Reverse Stock Split") of its common stock at a ratio of 1-for-150.

globenewswire.com

Jan 23

Curative Biotechnology Announces Canadian Patent Allowance

“Druggable Target to Treat Retinal Degeneration” Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing metformin-based eye drops for the treatment of degenerative eye diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled “Druggable Target to Treat Retinal Degeneration.

Company Profile

Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1998-03-30

Beta

1.42

Websitecurativebiotech.com↗